Literature DB >> 9218569

The generation of MHC class I-associated peptides is only partially inhibited by proteasome inhibitors: involvement of nonproteasomal cytosolic proteases in antigen processing?

A Vinitsky1, L C Antón, H L Snyder, M Orlowski, J R Bennink, J W Yewdell.   

Abstract

The proteasome is believed to participate in the generation of a large percentage of peptide ligands for MHC class I molecules. This conclusion is based largely on the activities of peptidyl aldehydes that block proteasome activity. We tested the ability of a panel of proteasome inhibitors to affect the generation of MHC class I binding peptides in mouse L929 cells. Included in the panel are peptidyl aldehydes and a microbial product, lactacystin, that blocks proteasome activity in a distinct and more specific manner. Contrary to expectations, proteasome inhibitors failed to block the generation of a large portion of high affinity peptides as inferred by measuring cell surface expression of newly synthesized MHC class I molecules. These findings were confirmed by examining the effects of the inhibitors on the presentation of individual antigenic determinants from endogenously synthesized or exogenously delivered influenza virus proteins. Presentation of peptides derived from exogenous basic polymerase 1, endogenous basic polymerase 1, and nonstructural-1 proteins was decreased by inhibitors in a manner consistent with proteasomal involvement. Presentation of peptides derived from endogenous nucleoprotein was not significantly affected by the proteasome inhibitors, while presentation of exogenous hemagglutinin and nucleoprotein was enhanced by the proteasome inhibitors. These data are consistent with the involvement of both proteasomes and nonproteasomal cytosolic proteases in the generation of a significant portion of MHC class I binding peptides.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9218569

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses.

Authors:  K Schwarz; R de Giuli; G Schmidtke; S Kostka; M van den Broek; K B Kim; C M Crews; R Kraft; M Groettrup
Journal:  J Immunol       Date:  2000-06-15       Impact factor: 5.422

2.  Intracellular delivery of a cytolytic T-lymphocyte epitope peptide by pertussis toxin to major histocompatibility complex class I without involvement of the cytosolic class I antigen processing pathway.

Authors:  N H Carbonetti; T J Irish; C H Chen; C B O'Connell; G A Hadley; U McNamara; R G Tuskan; G K Lewis
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

3.  Proteasome inhibitors induce the presentation of an Epstein-Barr virus nuclear antigen 1-derived cytotoxic T lymphocyte epitope in Burkitt's lymphoma cells.

Authors:  Federica Destro; Fabio Sforza; Mariaconcetta Sicurella; Diego Marescotti; Eleonora Gallerani; Anna Baldisserotto; Mauro Marastoni; Riccardo Gavioli
Journal:  Immunology       Date:  2011-02-22       Impact factor: 7.397

Review 4.  Generation of MHC class I ligands in the secretory and vesicular pathways.

Authors:  Margarita Del Val; Salvador Iborra; Manuel Ramos; Silvia Lázaro
Journal:  Cell Mol Life Sci       Date:  2011-03-09       Impact factor: 9.261

5.  Ribosomal Proteins Regulate MHC Class I Peptide Generation for Immunosurveillance.

Authors:  Jiajie Wei; Rigel J Kishton; Matthew Angel; Crystal S Conn; Nicole Dalla-Venezia; Virginie Marcel; Anne Vincent; Frédéric Catez; Sabrina Ferré; Lilia Ayadi; Virginie Marchand; Devin Dersh; James S Gibbs; Ivaylo P Ivanov; Nathan Fridlyand; Yohann Couté; Jean-Jacques Diaz; Shu-Bing Qian; Louis M Staudt; Nicholas P Restifo; Jonathan W Yewdell
Journal:  Mol Cell       Date:  2019-01-31       Impact factor: 17.970

6.  The effect of proteasome inhibition on the generation of the human leukocyte antigen (HLA) peptidome.

Authors:  Elena Milner; Lilach Gutter-Kapon; Michal Bassani-Strenberg; Eilon Barnea; Ilan Beer; Arie Admon
Journal:  Mol Cell Proteomics       Date:  2013-03-28       Impact factor: 5.911

7.  Varied Role of Ubiquitylation in Generating MHC Class I Peptide Ligands.

Authors:  Jiajie Wei; Damien Zanker; Anthony R Di Carluccio; Margery G Smelkinson; Kazuyo Takeda; Mina O Seedhom; Devin Dersh; James S Gibbs; Ning Yang; Ajit Jadhav; Weisan Chen; Jonathan W Yewdell
Journal:  J Immunol       Date:  2017-03-31       Impact factor: 5.422

8.  Accelerated HER-2 degradation enhances ovarian tumor recognition by CTL. Implications for tumor immunogenicity.

Authors:  A Castilleja; N E Ward; C A O'Brian; B Swearingen; E Swan; M A Gillogly; J L Murray; A P Kudelka; D M Gershenson; C G Ioannides
Journal:  Mol Cell Biochem       Date:  2001-01       Impact factor: 3.396

9.  CD4 glycoprotein degradation induced by human immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the ubiquitin-conjugating pathway.

Authors:  U Schubert; L C Antón; I Bacík; J H Cox; S Bour; J R Bennink; M Orlowski; K Strebel; J W Yewdell
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

10.  Bioactive 5,6-dihydro-alpha-pyrone derivatives from Hyptis brevipes.

Authors:  Ye Deng; Marcy J Balunas; Jeong-Ah Kim; Daniel D Lantvit; Young-Won Chin; Heebyung Chai; Sugeng Sugiarso; Leonardus B S Kardono; Harry H S Fong; John M Pezzuto; Steven M Swanson; Esperanza J Carcache de Blanco; A Douglas Kinghorn
Journal:  J Nat Prod       Date:  2009-06       Impact factor: 4.050

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.